PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 04: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 06: MARKET SEGMENTATION BY TYPE • Market segmentation by type • Comparison by type • Ischemic stroke - Market size and forecast 2018-2023 • Hemorrhagic stroke - Market size and forecast 2018-2023 • Market opportunity by type PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • North America - Market size and forecast 2018-2023 • Europe - Market size and forecast 2018-2023 • Asia - Market size and forecast 2018-2023 • ROW - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 11: MARKET TRENDS • Development of novel therapies • Increasing awareness about stroke • Strategic alliances PART 12: VENDOR LANDSCAPE • Overview • Landscape disruption PART 13: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • Amgen Inc. • AstraZeneca Plc • Bayer AG • Boehringer Ingelheim International GmbH • Bristol-Myers Squibb Co. • F. Hoffmann-La Roche Ltd. • Johnson & Johnson Services Inc. • Merck & Co. Inc. • Pfizer Inc. • Sanofi PART 14: APPENDIX • Research methodology • List of abbreviations • Definition of market positioning of vendors PART 15: EXPLORE TECHNAVIO   Exhibit 01: Product overview Exhibit 02: Global pharmaceuticals market Exhibit 03: Segments of global pharmaceuticals market Exhibit 04: Market characteristics Exhibit 05: Market segments Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2018 Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 09: Global market: Year-over-year growth 2019-2023 (%) Exhibit 10: Five forces analysis 2018 Exhibit 11: Five forces analysis 2023 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2018 Exhibit 18: Type - Market share 2018-2023 (%) Exhibit 19: Comparison by type Exhibit 20: Ischemic stroke - Market size and forecast 2018-2023 ($ millions) Exhibit 21: Ischemic stroke - Year-over-year growth 2019-2023 (%) Exhibit 22: Hemorrhagic stroke - Market size and forecast 2018-2023 ($ millions) Exhibit 23: Hemorrhagic stroke - Year-over-year growth 2019-2023 (%) Exhibit 24: Market opportunity by type Exhibit 25: Customer landscape Exhibit 26: Market share by geography 2018-2023 (%) Exhibit 27: Geographic comparison Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 29: North America - Year-over-year growth 2019-2023 (%) Exhibit 30: Top 3 countries in North America Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 32: Europe - Year-over-year growth 2019-2023 (%) Exhibit 33: Top 3 countries in Europe Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 35: Asia - Year-over-year growth 2019-2023 (%) Exhibit 36: Top 3 countries in Asia Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 38: ROW - Year-over-year growth 2019-2023 (%) Exhibit 39: Top 3 countries in ROW Exhibit 40: Key leading countries Exhibit 41: Market opportunity Exhibit 42: Impact of drivers and challenges Exhibit 43: Vendor landscape Exhibit 44: Landscape disruption Exhibit 45: Vendors covered Exhibit 46: Vendor classification Exhibit 47: Market positioning of vendors Exhibit 48: Amgen Inc. - Vendor overview Exhibit 49: Amgen Inc. - Business segments Exhibit 50: Amgen Inc. - Organizational developments Exhibit 51: Amgen Inc. - Geographic focus Exhibit 52: Amgen Inc. - Key offerings Exhibit 53: Amgen Inc. - Key customers Exhibit 54: AstraZeneca Plc - Vendor overview Exhibit 55: AstraZeneca Plc - Business segments Exhibit 56: AstraZeneca Plc - Organizational developments Exhibit 57: AstraZeneca Plc - Geographic focus Exhibit 58: AstraZeneca Plc - Key offerings Exhibit 59: AstraZeneca Plc - Key customers Exhibit 60: Bayer AG - Vendor overview Exhibit 61: Bayer AG - Business segments Exhibit 62: Bayer AG - Organizational developments Exhibit 63: Bayer AG - Geographic focus Exhibit 64: Bayer AG - Segment focus Exhibit 65: Bayer AG - Key offerings Exhibit 66: Bayer AG - Key customers Exhibit 67: Boehringer Ingelheim International GmbH - Vendor overview Exhibit 68: Boehringer Ingelheim International GmbH - Business segments Exhibit 69: Boehringer Ingelheim International GmbH - Organizational developments Exhibit 70: Boehringer Ingelheim International GmbH - Geographic focus Exhibit 71: Boehringer Ingelheim International GmbH - Segment focus Exhibit 72: Boehringer Ingelheim International GmbH - Key offerings Exhibit 73: Boehringer Ingelheim International GmbH - Key customers Exhibit 74: Bristol-Myers Squibb Co. - Vendor overview Exhibit 75: Bristol-Myers Squibb Co. - Business segments Exhibit 76: Bristol-Myers Squibb Co. - Organizational developments Exhibit 77: Bristol-Myers Squibb Co. - Geographic focus Exhibit 78: Bristol-Myers Squibb Co. - Key offerings Exhibit 79: Bristol-Myers Squibb Co. - Key customers Exhibit 80: F. Hoffmann-La Roche Ltd. - Vendor overview Exhibit 81: F. Hoffmann-La Roche Ltd. - Business segments Exhibit 82: F. Hoffmann-La Roche Ltd. - Organizational developments Exhibit 83: F. Hoffmann-La Roche Ltd. - Geographic focus Exhibit 84: F. Hoffmann-La Roche Ltd. - Segment focus Exhibit 85: F. Hoffmann-La Roche Ltd. - Key offerings Exhibit 86: F. Hoffmann-La Roche Ltd. - Key customers Exhibit 87: Johnson & Johnson Services Inc. - Vendor overview Exhibit 88: Johnson & Johnson Services Inc. - Business segments Exhibit 89: Johnson & Johnson Services Inc. - Organizational developments Exhibit 90: Johnson & Johnson Services Inc. - Geographic focus Exhibit 91: Johnson & Johnson Services Inc. - Segment focus Exhibit 92: Johnson & Johnson Services Inc. - Key offerings Exhibit 93: Johnson & Johnson Services Inc. - Key customers Exhibit 94: Merck & Co. Inc. - Vendor overview Exhibit 95: Merck & Co. Inc. - Business segments Exhibit 96: Merck & Co. Inc. - Organizational developments Exhibit 97: Merck & Co. Inc. - Geographic focus Exhibit 98: Merck & Co. Inc. - Segment focus Exhibit 99: Merck & Co. Inc. - Key offerings Exhibit 100: Merck & Co. Inc. - Key customers Exhibit 101: Pfizer Inc. - Vendor overview Exhibit 102: Pfizer Inc. - Business segments Exhibit 103: Pfizer Inc. - Organizational developments Exhibit 104: Pfizer Inc. - Geographic focus Exhibit 105: Pfizer Inc. - Segment focus Exhibit 106: Pfizer Inc. - Key offerings Exhibit 107: Pfizer Inc. - Key customers Exhibit 108: Sanofi - Vendor overview Exhibit 109: Sanofi - Business segments Exhibit 110: Sanofi - Organizational developments Exhibit 111: Sanofi - Geographic focus Exhibit 112: Sanofi - Segment focus Exhibit 113: Sanofi - Key offerings Exhibit 114: Sanofi - Key customers Exhibit 115: Validation techniques employed for market sizing Exhibit 116: Definition of market positioning of vendors

Amgen Inc., AstraZeneca Plc, Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., Merck & Co. Inc., Pfizer Inc., and Sanofi.